urinary%20tract%20infection%20-%20complicated
URINARY TRACT INFECTION - COMPLICATED
Urinary tract infection (UTI) is complicated if the UTI is associated with factors that increases colonization and decreases therapy efficacy. Factors may include one or all of the following: Structural or functional abnormalities of the genitourinary tract; presence of an underlying disease that interferes with host defense mechanisms or the patient being immunocompromised; and being infected by a multi-drug resistant bacteria.
Principles of therapy includes effective antimicrobial antimicrobial therapy, optimal management of the underlying abnormalities or other diseases & adequate life-supporting measures.

Definition

  • Urinary tract infection (UTI) associated w/ a condition [eg structural or functional abnormalities of the genitourinary tract (GUT)] or the presence of an underlying disease that interferes w/ host defense mechanisms, which increases the risks of acquiring infection, failing therapy or having recurrent infections
  • Associated w/ altered microbiology that favors more antimicrobial resistant strains that are sometimes less virulent than those found in uncomplicated UTI

Etiology

  • The spectrum of bacteria causing complicated urinary tract infection (UTI) is much larger than that of uncomplicated UTI & more likely to be antibiotic-resistant
    • Escherichia coli, Proteus, Klebsiella, Pseudomonas, Serratia spp & enterococci are the usual strains found in urine culture
  • Catheter-associated UTI
    • Short-term (<1 week): E coli, Pseudomonas aeruginosa
    • Long-term (>1 week): Proteus mirabilis, E coli, P aeruginosa, Providencia stuartii, Morganella morganii, Citrobacter sp, Enterobacter sp, Enterococcus sp, Candida spp
  • Diabetes mellitus (DM) patients: E coli, Klebsiella pneumoniae, P mirabilis, P aeruginosa, Enterobacter sp, Enterococcus sp, Candida spp
  • Renal transplant patients: E coli, P mirabilis, K pneumoniae, P aeruginosa, Gram-positive cocci, Enterobacter sp, Enterococci sp, Serratia sp, Acinetobacter sp, Citrobacter spp, Corynebacterium urealyticum
  • Neutropenic patients: Gram-negative bacilli especially P aeruginosa, Staphylococcus aureus, Candida sp
  • Patients w/ anatomic abnormalities: E coli, K pneumoniae, P aeruginosa, P mirabilis

Signs and Symptoms

  • A complicated urinary tract infection (UTI) does not necessarily present w/ clinical symptoms
  • Dysuria, urgency, frequency, flank pain, costovertebral angle tenderness, suprapubic pain & fever may or may not be present
  • May present w/ signs of sepsis: Hypotension, temperature >40°C, tender subcostal or intractable nausea & vomiting
  • Symptoms may vary from severe obstructive acute pyelonephritis w/ imminent urosepsis up to a catheter-associated post-op UTI
  • Concomitant medical conditions [eg diabetes mellitus (DM), renal failure] are often present

Risk Factors

Factors that suggest a potential complicated urinary tract infection (UTI):
  • >7 days of symptoms prior to presentation
  • Azotemia due to intrinsic renal disease
  • Chemical or radiation injuries of the uroepithelium
  • Comorbidities that predispose to papillary necrosis (eg sickle cell disease, severe DM, analgesic abuse, Pseudomonas sp infection)
  • Elderly
  • Healthcare-associated infection
  • Immunosuppression
  • Incomplete bladder emptying w/ >100 mL of residual urine
  • Male sex
    • Unless it is the 1st episode of symptomatic lower UTI occurring in young (15-40 years old) otherwise healthy, sexually active male w/ no history/clinical evidence of structural or functional urologic abnormality
  • Obstructive uropathy (eg bladder outlet obstruction, calculi, stones, stricture, tumor)
  • Peri- & postoperative UTI
  • Presence of an indwelling urinary catheter or use of intermittent bladder catheterization
  • Recent antimicrobial use
  • Recent urinary tract intervention
  • Renal insufficiency & transplantation
  • Unresolved UTI due to failed response to antibiotic therapy
  • Urinary tract modifications (eg ileal loop or pouch)
  • Vesicoureteral reflux or other functional abnormalities
  • Residence in an institution providing extended care
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
15 Nov 2017
New drug applications approved by US FDA as of 1 - 15 November 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
29 Oct 2017
There is insufficient evidence to support the exclusive use of azole therapies for leishmaniasis, as itraconazole, ketoconazole and fluconazole all have similar but modest efficacy rates, according to a new meta-analysis.